PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ARCA biopharma, Inc. (ABIO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US00211Y5069

CUSIP

00211Y506

Sector

Healthcare

IPO Date

Aug 8, 1997

Highlights

Market Cap

$34.82M

EPS (TTM)

-$5.88

Gross Profit (TTM)

-$31.00K

EBITDA (TTM)

-$5.20M

Year Range

$2.22 - $33.00

Target Price

$7.00

Short %

48.08%

Short Ratio

62.38

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
ABIO vs. GME
Popular comparisons:
ABIO vs. GME

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ARCA biopharma, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Jul 21Jul 28Aug 04Aug 11Aug 18Aug 25September
-100.00%
-3.96%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Returns By Period


ABIO

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.93%

1M

-3.71%

6M

3.77%

1Y

21.81%

5Y*

12.17%

10Y*

11.26%

*Annualized

Monthly Returns

The table below presents the monthly returns of ABIO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-6.47%3.77%6.67%98.29%6.02%3.51%-21.67%-87.35%-77.68%
2023-7.17%0.00%-9.55%0.50%5.50%-3.79%0.49%0.49%-1.95%-10.95%1.68%-6.59%-28.27%
2022-12.09%7.41%13.30%3.04%0.84%4.18%-1.61%-4.49%-11.97%4.37%-2.79%13.40%10.23%
20214.74%0.24%-13.30%-5.75%1.45%0.00%-9.46%-2.22%-4.21%-7.43%-13.69%-9.09%-46.38%
2020-8.21%-28.65%-25.40%31.18%244.26%-47.46%5.74%-21.71%-19.34%-12.90%10.13%-5.42%-29.78%
201925.91%12.81%-21.13%-23.27%12.21%26.43%-6.42%-17.96%-4.81%-7.47%13.13%1.98%-4.87%
201822.22%-50.91%-38.35%5.11%5.93%0.00%49.28%-25.78%-9.09%21.43%-24.16%-35.33%-75.30%
2017-7.02%-3.77%0.00%3.92%-9.43%-0.00%-22.92%-40.54%4.55%5.39%7.26%3.85%-52.63%
2016-18.49%-9.23%0.87%21.33%-20.31%-13.56%6.21%-7.79%-0.35%-22.26%6.82%21.28%-38.71%
2015-25.55%-1.41%12.87%1.25%-1.25%45.57%-6.96%-15.89%-21.27%3.23%12.89%-19.55%-30.34%
201416.07%-3.59%-1.06%-13.44%-8.70%-0.68%-2.06%-2.09%-11.43%-9.68%-26.92%16.51%-43.24%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ABIO is 20, meaning it’s performing worse than 80% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of ABIO is 2020
Overall Rank
The Sharpe Ratio Rank of ABIO is 1414
Sharpe Ratio Rank
The Sortino Ratio Rank of ABIO is 3535
Sortino Ratio Rank
The Omega Ratio Rank of ABIO is 4646
Omega Ratio Rank
The Calmar Ratio Rank of ABIO is 55
Calmar Ratio Rank
The Martin Ratio Rank of ABIO is 00
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ARCA biopharma, Inc. (ABIO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
ABIO
^GSPC

There is not enough data available to calculate the Sharpe ratio for ARCA biopharma, Inc.. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00Jul 21Jul 28Aug 04Aug 11Aug 18Aug 25September
-0.58
1.66
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History

ARCA biopharma, Inc. provided a 861.25% dividend yield over the last twelve months, with an annual payout of $20.67 per share.


PeriodTTM
Dividend$20.67

Dividend yield

861.25%

Monthly Dividends

The table displays the monthly dividend distributions for ARCA biopharma, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024$20.67$0.00$20.67

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%Jul 21Jul 28Aug 04Aug 11Aug 18Aug 25September
-100.00%
-4.57%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ARCA biopharma, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ARCA biopharma, Inc. was 100.00%, occurring on Aug 30, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Dec 11, 20064460Aug 30, 2024
-79.63%Aug 3, 1999890Feb 18, 2003727Jan 5, 20061617
-25.59%Mar 8, 199924Apr 9, 199958Jul 1, 199982

Volatility

Volatility Chart

The current ARCA biopharma, Inc. volatility is 257.75%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%200.00%250.00%Jul 21Jul 28Aug 04Aug 11Aug 18Aug 25September
257.75%
4.88%
ABIO (ARCA biopharma, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ARCA biopharma, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for ARCA biopharma, Inc..


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab